Thiabendazole Treatment of Severe Strongyloidiasis in a Hemodialyzed Patient

Brief Reports1 November 1978Thiabendazole Treatment of Severe Strongyloidiasis in a Hemodialyzed PatientJAMES D. SCHUMAKER, B.S., JEFFREY D. BAND, M.D., GARY L. LENSMEYER, B.S., WILLIAM A. CRAIG, M.D.JAMES D. SCHUMAKER, B.S.Search for more papers by this author, JEFFREY D. BAND, M.D.Search for more papers by this author, GARY L. LENSMEYER, B.S.Search for more papers by this author, WILLIAM A. CRAIG, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-89-5-644 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe progression of asymptomatic or mildly symptomaticStrongyloides stercoralsinfection to the often fatal hyperinfected state is a well documented complication of immunosuppression (1). Several deaths have been reported in renal transplant recipients given immunosuppressive therapy (2). Although thiabendazole is the preferred treatment for strongyloides, the results of conventional 48-h therapy have been disappointing in the hyperinfected patient. Therefore, therapy for as long as 5 days has been recommended (3). Because thiabendazole is rapidly metabolized to 5-hydroxy-metabolites, which are eliminated predominantly by the kidney, the dosage may need to be modified with longer therapy in patients with renal failure. We...References1. RIVERAMALDONADOVÉLEZ-GARCÍAGRILLOMALARET ENEAG: Hyperinfection syndrome with Strongyloides stercoralis. Ann Intern Med 72:199-204, 1970 LinkGoogle Scholar2. FAGUNDESBUSATOBRENTANO LOL: Strongyloidiasis: fatal complication of renal transplantation. Lancet 2:439-440, 1971 CrossrefGoogle Scholar3. Drugs for parasitic infections. Med Lett Drugs Ther 20:17-24, 1978 MedlineGoogle Scholar4. . Evaluation of a broad-spectrum anthelminic. Thiabendazole (Mintezol). JAMA 205:172-173, 1968 CrossrefMedlineGoogle Scholar5. TOCCOROSENBLUMMARTINROBINSON DCCJ: Absorption, metabolism and excretion of thiabendazole in man and laboratory animals. Toxicol Appl Pharmacol 9:31-39, 1966 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: The University of Wisconsin Hospitals William S. Middleton Memorial Veterans Administration Hospital Madison, Wisconsin PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByParasitic InfectionsInfection in the Organ Transplant RecipientIdentification of human and rabbit cytochromes P450 1A2 as major isoforms involved in thiabendazole 5-hydroxylationInfections in solid-organ transplant recipientsInfection in the Organ Transplant RecipientTTPharmacological Considerations for Renal Failure and DialysisInfection in the Renal and Liver Transplant PatientParasitic InfectionsPharmacological Aspects of Renal Failure and DialysisDetermination of thiabendazole and 5-hydroxythiabendazole in human serum by fluorescence-detected high-performance liquid chromatographyThe Pharmacokinetics of Thiabendazole and its Metabolites in an Anephric Patient Undergoing Hemodialysis and HemoperfusionTreatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectivenessClinical features of Strongyloides stercoralis infection in an endemic area of the United StatesDrugs and the Kidney 1 November 1978Volume 89, Issue 5_Part_1Page: 644-645KeywordsImmunosuppressivesKidneysRenal failureRenal transplantation Issue Published: 1 November 1978 PDF DownloadLoading ...

Topic: Parasites and Host Interactions
Subfield: Parasitology
Field: Immunology and Microbiology
Domain: Life Sciences